Trial reportTrials2009
VITA-D: cholecalciferol substitution in vitamin D deficient kidney transplant recipients: a randomized, placebo-controlled study to evaluate the post-transplant outcome.
Trial report in Trials, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 33 citations in OpenAlex.
- Trial
- Review
- Bone and Mineral Disorder in Renal Transplant Patients: Overview of Pathology, Clinical, and Therapeutic Aspects.Frontiers in medicine · 2022Review
- Interventions for preventing bone disease in kidney transplant recipients.The Cochrane database of systematic reviews · 2019Review
- Raising awareness on the therapeutic role of cholecalciferol in CKD: a multidisciplinary-based opinion.Endocrine · 2018Review
- Mineral and Bone Disorders After Kidney Transplantation.Frontiers in medicine · 2018Review
- Paricalcitol Versus Calcifediol for Treating Hyperparathyroidism in Kidney Transplant Recipients.Kidney international reports · 2018Article
- Current evidence on vitamin D deficiency and kidney transplant: What's new?Reviews in endocrine & metabolic disorders · 2017Review
- Impact of seasonality on the dynamics of native Vitamin D repletion in long-term renal transplant patients.Clinical kidney journal · 2017Article
- Review
- The impact of vitamin D deficiency on patients undergoing kidney transplantation: focus on cardiovascular, metabolic, and endocrine outcomes.Endocrine · 2015Review
- Vitamin D in renal transplantation - from biological mechanisms to clinical benefits.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons · 2014Review
- Calcidiol deficiency in end-stage organ failure and after solid organ transplantation: status quo.Nutrients · 2013Review
- The impact of pretransplant 25-hydroxy vitamin D deficiency on subsequent graft function: an observational study.BMC nephrology · 2012Article
- The immunoregulatory function of vitamin D: implications in chronic kidney disease.Nature reviews. Nephrology · 2012Review
- Clinical impact of hypercalcemia in kidney transplant.International journal of nephrology · 2011Article
- Possible renoprotection by vitamin D in chronic renal disease: beyond mineral metabolism.Nature reviews. Nephrology · 2009Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundVitamin D does not only regulate calcium homeostasis but also plays an important role as an immune modulator. It influences the immune system through the induction of immune shifts and regulatory cells resulting in immunologic tolerance. As such, vitamin D is thought to exert beneficial effects within the transplant setting, especially in kidney transplant recipients, considering the high prevalence of vitamin D deficiency in kidney transplant recipients. METHODS/
designThe VITA-D study, a randomized, placebo-controlled, double-blind study with two parallel groups including a total of 200 kidney transplant recipients, is designed to investigate the immunomodulatory and renoprotective effects of cholecalciferol (vitamin D3) within the transplant setting. Kidney transplant recipients found to have vitamin D deficiency defined as 25-hydroxyvitamin D3 < 50 nmol per liter will be randomly assigned to receive either oral cholecalciferol therapy or placebo and will be followed for one year. Cholecalciferol will be administered at a dose of 6800 International Units daily over a time period of one year. The objective is to evaluate the influence of vitamin D3 substitution in vitamin D deficient kidney transplant recipients on the post-transplant outcome. As a primary endpoint glomerular filtration rate calculated with the MDRD formula (modification of diet in renal disease) one year after kidney transplantation will be evaluated. Incidence of acute rejection episodes, and the number and severity of infections (analyzed by means of C-reactive protein) within the first year after transplantation will be monitored as well. As a secondary endpoint the influence of vitamin D3 on bone mineral density within the first year post-transplant will be assessed. Three DXA analyses will be performed, one within the first four weeks post-transplant, one five months and one twelve months after kidney transplantation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.